Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.

Zyprexa® (Olanzapine), an antipsychotic, is commonly used to treat schizophrenia, bipolar 1, and related agitation.

Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.

Zelenirstat, an effective oral NMT inhibitor, showed promising results in treating advanced relapsed/refractory cancer at 2024's ASCO_GI.

Galderma declares submission approval of Nemolizumab for treating Prurigo Nodularis and Eczema in America and Europe.

Vesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia.

Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.

Tinengotinib, a selective multi-kinase inhibitor, effectively targets FGFR2 fusion/rearrangement and resistance mutations in early trials involving cholangiocarcinoma patients.

CSL Reveals Key Findings of Phase 3 AEGIS-II Study Assessing Effectiveness and Security of CSL112 (Human Apolipoprotein A-I).

Clopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997.

Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.

Tasurgratinib (E7090) is an orally available selective inhibitor of FGFR 1–3, the recommended dose is 140 mg per day per the dose-escalation part of a first-in-human phase 1 study.